Amarin Corporation PLC Announces Submission of Supplemental New Drug Application for Chemport, Inc. as an Additional Vascepa® Active Pharmaceutical Ingredient Supplier

Published: Dec 19, 2012

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Chemport, Inc. as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.

Back to news